share_log

Bristol-Myers Squibb | DEF 14A: Definitive information statements

Bristol-Myers Squibb | DEF 14A: Definitive information statements

施貴寶 | DEF 14A：股東委託書決議
SEC announcement ·  03/29 10:39
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMS) announced the upcoming virtual Annual Meeting of Shareholders scheduled for May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor for 2024, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, two shareholder proposals will be considered, one advocating for an independent Board Chair and another on executive stock retention. The Board recommends votes for all directors, executive compensation, auditor ratification, and the charter amendment, but against the shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner taking over as CEO and Board Chair following Dr. Giovanni Caforio's retirement. The company's proxy materials, including this announcement, are available as of March 28, 2024.
Bristol-Myers Squibb (BMS) announced the upcoming virtual Annual Meeting of Shareholders scheduled for May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor for 2024, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, two shareholder proposals will be considered, one advocating for an independent Board Chair and another on executive stock retention. The Board recommends votes for all directors, executive compensation, auditor ratification, and the charter amendment, but against the shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner taking over as CEO and Board Chair following Dr. Giovanni Caforio's retirement. The company's proxy materials, including this announcement, are available as of March 28, 2024.
百時美施貴寶（BMS）宣佈即將於2024年5月7日舉行的虛擬年度股東大會。截至2024年3月14日，登記在冊的股東有權對幾項關鍵提案進行投票，包括選舉10名董事會董事、關於高管薪酬的諮詢投票、批准德勤會計師事務所作爲2024年獨立核數師以及對有限高管人員免責的公司註冊證書修正案。此外，將考慮兩項股東提案，一項主張獨立董事會主席，另一項提倡保留高管股票。董事會建議投票支持所有董事、高管薪酬、核數師批准和章程修正案，但反對股東提案。會議還將討論首席執行官的過渡問題，喬瓦尼·卡福里奧博士退休後，克里斯托弗·博爾納博士將接任首席執行官兼董事會主席。該公司的代理材料，包括本公告，將於2024年3月28日公佈。
百時美施貴寶（BMS）宣佈即將於2024年5月7日舉行的虛擬年度股東大會。截至2024年3月14日，登記在冊的股東有權對幾項關鍵提案進行投票，包括選舉10名董事會董事、關於高管薪酬的諮詢投票、批准德勤會計師事務所作爲2024年獨立核數師以及對有限高管人員免責的公司註冊證書修正案。此外，將考慮兩項股東提案，一項主張獨立董事會主席，另一項提倡保留高管股票。董事會建議投票支持所有董事、高管薪酬、核數師批准和章程修正案，但反對股東提案。會議還將討論首席執行官的過渡問題，喬瓦尼·卡福里奧博士退休後，克里斯托弗·博爾納博士將接任首席執行官兼董事會主席。該公司的代理材料，包括本公告，將於2024年3月28日公佈。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。